Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2020-11-05 Earnings Release
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company issued a press release announcing its financial results for the quarterly period ended September 30, 2020. The press release is attached as an exhibit and is being furnished, not filed, under Item 2.02. The document itself does not contain detailed financial statements or substantive financial data but rather announces the earnings release. The length is 3538 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement within a Form 8-K filing.
2020-11-05 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-05 English
PRIMARY DOCUMENT
Director's Dealing
2020-10-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a settlement agreement between Collegium Pharmaceutical, Inc. and Teva Pharmaceuticals USA, Inc. resolving patent litigation. It includes details about the settlement terms, references to exhibits (settlement agreement and press release), and signatures. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a material definitive agreement and related information, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like M&A filings or earnings releases. The length is about 5,044 characters, which is consistent with a detailed regulatory announcement rather than a full report.
2020-09-30 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-28 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.